埃奇纳科西德通过调节巨细胞两极化来改善白素诱导的异常性肺纤维化
Yifan Zhang1, Liming Fan1, Mengni Wang2
1Department of Respiratory and Critical Care Medicine, Jingzhou No.1 People's Hospital, Jingzhou, 434000, China.
Journal of molecular histology
|November 24, 2025
概括
乙化 (ECH) 通过减少动物模型中的肺炎和纤维化,有效治疗异常性肺纤维化 (IPF). 这种天然化合物通过JAK2 / STAT3通路抑制亲纤维M2巨细胞极化,显示为IPF治疗的潜力.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 异形性肺纤维化 (IPF) 是一种慢性,进展性肺病,病因不明.
- Echinacoside (ECH),来自Cistanche deserticola,具有已知的抗氧化和抗炎性质.
- ECH已经证明对各种纤维状疾病有保护作用.
研究的目的:
- 评估 Echinacoside (ECH) 在治疗异常性肺纤维化 (IPF) 的治疗潜力.
- 在IPF的细胞和动物模型中研究ECH抗纤维效应的潜在机制.
主要方法:
- 已确定的白素 (BLM) 诱导的IPF小鼠模型和转化生长因子 (TGF) -β1治疗的人类肺纤维细胞 (MRC-5).
- 给模型和评估的肺组织学变化,基因/蛋白质表达 (纤维化标志物,M2巨细胞,JAK2/STAT3) 和支气管洗液 (BALF) 中的炎症/纤维化因素.
- 用CCK-8和伤口愈合试验在体外评估细胞活力和迁移.
主要成果:
- 在BLM诱导的IPF小鼠中,ECH显著降低了肺炎和纤维化.
- ECH降低了炎症性细胞因子,TGF-β和氧含量,同时抑制了与纤维化相关的标记物 (α-SMA,纤维素,COL1A1) 和肺组织中的M2巨标记物.
- 在体外,ECH抑制了TGF-β1诱导的纤维化标志物上调和MRC-5细胞中的细胞迁移.
- 在体内和体外,ECH抑制了JAK2/STAT3信号通路.
结论:
- 乙化 (ECH) 在异常性肺纤维化 (IPF) 中显示出显著的抗纤维化作用.
- 通过抑制亲纤维的M2巨细胞极化,ECH可以缓解IPF,这可能是通过降低JAK2/STAT3通路的调节.
- 在IPF治疗中,ECH是一个有前途的治疗候选药物.
更多相关视频
相关概念视频
Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
Chronic Obstructive Pulmonary Disease II: Emphysema
48
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
48


